FMR LLC increased its holdings in Rapport Therapeutics (NASDAQ:RAPP - Free Report) by 10.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,486,468 shares of the company's stock after purchasing an additional 503,117 shares during the period. FMR LLC owned approximately 15.00% of Rapport Therapeutics worth $112,363,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in RAPP. Values First Advisors Inc. bought a new position in shares of Rapport Therapeutics during the third quarter valued at about $31,000. SG Americas Securities LLC purchased a new stake in Rapport Therapeutics during the 3rd quarter valued at about $101,000. Sandia Investment Management LP purchased a new position in Rapport Therapeutics in the 2nd quarter worth approximately $116,000. Davidson Kempner Capital Management LP purchased a new position in Rapport Therapeutics in the 2nd quarter worth approximately $229,000. Finally, Squarepoint Ops LLC bought a new stake in Rapport Therapeutics in the second quarter valued at approximately $380,000.
Rapport Therapeutics Stock Performance
Shares of Rapport Therapeutics stock traded down $1.29 on Thursday, hitting $20.27. The stock had a trading volume of 116,996 shares, compared to its average volume of 153,899. Rapport Therapeutics has a one year low of $16.55 and a one year high of $29.74. The firm has a 50-day moving average of $23.19.
About Rapport Therapeutics
(
Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Further Reading
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
